Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
June 18 2024 - 3:17PM
Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech pioneer
developing off-the-shelf, genetically unmodified T cell
therapeutics in oncology, neurology, and virology, highlights the
commentary of Mittul Mehta, Tevogen’s Chief Information Officer and
Head of Tevogen.AI, at the Longwood Spring MIT Conference. Mehta
emphasized the transformative potential of Tevogen Bio’s innovative
T cell technology and the company’s groundbreaking approach to
overcoming industry challenges.
Key Points from Mehta’s Commentary
Realizing the Full Potential of T Cell Therapies. Mehta
emphasized that the full potential of T cell-based therapies
remains untapped due to various limitations, including the
imbalance between the cost of manufacturing and reimbursement
rates.
Development of a New Class of T Cell Therapies. Mehta
highlighted that Tevogen is leading the development of a potential
new class of T cell therapies for treatment of acute viral
infections, long-term consequences of viral infections such as Long
COVID, viral- and non-viral-induced cancers, and certain
neurological disorders, including multiple sclerosis.
Overcoming Common Challenges Faced by the Industry with the
CAR-T Approach. Mehta discussed that product candidates from
company’s proprietary ExacTcell™ platform are designed to:
- Mainstream cell therapy through
off-the-shelf outpatient administration focusing on diseases that
impact large patient populations.
- Eliminate side effects associated
with traditional CAR-based T cell therapies.
- Significantly reduce manufacturing
costs. Mehta pointed out that Tevogen has achieved the production
of hundreds of doses from a single donor for its recently completed
clinical trial.
Industry’s First Attempt to Develop T Cell-Based Therapies for
Large Patient Populations. Mehta discussed how Tevogen designed its
entire business approach, from future pricing strategies to
large-scale cell therapy manufacturing plans. He highlighted that
speed and cost efficiency are critical to the future of the
industry, and that Tevogen believes it is poised to serve as a
model for others.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Leadership believes that sustainability and commercial
success in the current era of healthcare rely on ensuring patient
accessibility through advanced science and innovative business
models. Tevogen has reported positive safety data from its
proof-of-concept clinical trial, and its key intellectual property
assets are wholly owned by the company, not subject to any
third-party licensing agreements. These assets include three
granted patents, nine pending US and twelve ex-US pending patents,
two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry
leaders and distinguished scientists with drug development and
global product launch experience. Tevogen’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements,
including without limitation statements relating to: expectations
regarding the healthcare and biopharmaceutical industries;
Tevogen’s development of, the potential benefits of, and patient
access to its product candidates for the treatment of infectious
diseases, cancer and neurological disorders, including TVGN 489 for
the treatment of COVID-19 and Long COVID; Tevogen’s ability to
develop additional product candidates, including through use of
Tevogen’s ExacTcell platform; the anticipated benefits of
ExacTcell; expectations regarding Tevogen’s future clinical trials;
Tevogen’s manufacturing plans; and Tevogen’s ability to generate
revenue in the future. Forward-looking statements can sometimes be
identified by words such as “may,” “could,” “would,” “expect,”
“possible,” “potential,” “goal,” “opportunity,” “project,”
“believe,” “future,” and similar words and expressions or their
opposites. These statements are based on management’s expectations,
assumptions, estimates, projections and beliefs as of the date of
this presentation and are subject to a number of factors that
involve known and unknown risks, delays, uncertainties and other
factors not under the company’s control that may cause actual
results, performance or achievements of the company to be
materially different from the results, performance or other
expectations expressed or implied by these forward-looking
statements.
These factors include, but are not limited to: that Tevogen will
need to raise additional capital to execute its business plan,
which may not be available on acceptable terms or at all;
uncertainties inherent in the execution, cost, and completion of
preclinical studies and clinical trials; risks related to
regulatory review, and approval and commercial development; risks
associated with intellectual property protection; the effect of the
recent business combination with Semper Paratus Acquisition
Corporation (the “Business Combination”) on Tevogen’s business
relationships, operating results, and business generally; costs
related to the Business Combination and the failure to realize
anticipated benefits of the Business Combination; the outcome of
any legal proceedings that may be instituted against Tevogen
related to the Business Combination; changes in the markets in
which Tevogen competes, including with respect to its competitive
landscape, technology evolution, or regulatory changes; changes in
domestic and global general economic conditions; the risk that
Tevogen may not be able to execute its growth strategies or may
experience difficulties in managing its growth and expanding
operations; the risk that Tevogen may not be able to develop and
maintain effective internal controls; the failure to achieve
Tevogen’s commercialization and development plans, and identify and
realize additional opportunities, which may be affected by, among
other things, competition, the ability of Tevogen to grow and
manage growth economically and hire and retain key employees; the
risk that Tevogen may fail to keep pace with rapid technological
developments to provide new and innovative products and services or
make substantial investments in unsuccessful new products and
services; the ability to develop, license or acquire new
therapeutics; the risk of regulatory lawsuits or proceedings
relating to Tevogen’s business; Tevogen’s limited operating
history; and those factors discussed in Tevogen’s Annual Report on
Form 10-K and other filings with the SEC.
You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. Tevogen
undertakes no obligation to update any forward-looking statements,
except as required by applicable law.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGNW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tevogen Bio (NASDAQ:TVGNW)
Historical Stock Chart
From Sep 2023 to Sep 2024